NCT03034486已完成1 期
A Single Sequence, 3-period, Multiple-dose Study to Evaluate the Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930 in Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- AUCtau,ss of D930
研究概览
简要总结
This study is a single sequence, 3-period, multiple-dose study to evaluate the pharmacokinetics of D565 and the drug effect of D565 on pharmacokinetic characteristics of D930 in healthy male volunteers.
详细描述
This study is a single sequence, 3-period, multiple-dose study to evaluate the pharmacokinetics of D565 and the drug effect of D565 on pharmacokinetic characteristics of D930 in healthy male volunteers.
Subjects will receive D565 just one time on period 1 for evaluate the pharmacokinetics. And afterward, subjects will receive multiple dose of D930 for 9 days, and D565 with D930 for 9 days to evaluate the drug effect on period 2 and 3.
When period 1 finished, there are 3 days of washout period, but between period 2 and 3, there is no washout period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male older than 19 years and younger than 55 years at the time of screening
- •BMI 18.0~30.0(kg/m2) and body weight more than 55kg
- •Subject who has no chronic disease within last 3 years, no symptoms or pathological findings
- •Suitable subject who is determined by laboratory tests that hematology test, blood chemistry, urinalysis test according to the characteristics of the drug and 12-lead ECG at the time of screening
- •Subject who fully understand the purpose and content of clinical trials, characteristic of the drug after in-depth explanation, decided to join the clinical trials by their will and signed inform consent
- •Subject who has will and ability to participate in clinical trials
排除标准
- •Subject who has a history of clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, psychiatric, neurological, allergic or ophthalmic diseases (except for asymptomatic seasonal allergies not treated at the time of single administration) or who has a following history
- •Patients with liver failure or severe renal disease(CCr < 30ml/min) and cardiovascular patient (CCr is calculated by Cockroft and Gault formula)
- •Patients with acute occlusion angle glaucoma
- •Patients with a history of kidney stones
- •Patients with a history of chronic corneal injury and ophthalmic surgery
- •Patients with decreased endothelial cell count
- •Patients with renal tubular cells immature or with perchloric acidosis
- •Patients receiving MAO inhibitor
- •Patients taking antidepressants that affect noradrenaline delivery
- •Patients with depression, cerebral impairment or coronary artery disease, Raynode phenomenon, standing hypotension, and obstructive thromboangitis
- •Patients with bronchial asthma or history of asthma
- •Those who meet the following criteria on ophthalmological examination or test
- •A person with a history or suspected symptom of visual organs diseases including keratitis, iritis, uveitis, retinitis, dry eye syndrome, and strabismus.
- •Those who have had previous ophthalmic surgery or have undergone ophthalmic laser surgery within 6 months
- •Those whose corrected visual acuity measured at screening is 20/40 (acupuncture visual acuity chart 0.5) or less.
- •Those who have experienced side effects after wearing contact lenses, or who have worn contact lenses since the last month, who can not comply with the prohibition of wearing contact lenses during clinical trials
- •Others who have abnormal findings on ophthalmic examination
- •Patients with a history of gastrointestinal disorders (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple cecal surgery or hernia surgery) that may affect the absorption of pharmaceuticals for clinical trials
- •Clinical laboratory test results showing the following values
- •ALT or AST> 2 times upper limit of normal range
- •eGFR <60 mL / min / 1.73m2 calculated by the Modification of Diet in Renal Disease (MDRD)
- •When the systolic blood pressure is less than 100 mmHg or more than 150 mmHg or diastolic blood pressure is less than 60 mmHg or not less than 100 mmHg
- •Those who have received medication within 3 months prior to the first administration of the clinical trial drug by participating in other clinical trials or bioequivalence studies (However, the ending date of participation in the examination shall be the last day of medication.)
- •Those who have a history of drug abuse within the first year of screening
- •Persons who have been drinking continuously (21 units / week, 1 unit = 10 g of pure alcohol) within 6 months of the first dose or who can not abstain during the trial Example> Beer 5 ° 1 cup (250 ml) = 10 g, Soju 20 ° 1 cup (50 ml) = 8 g, Wine 12 ° 1 cup (125 ml) = 12 g
- •Those taking medication known to induce or inhibit drug metabolizing enzymes within 30 days prior to the first administration of clinical trial medication
- •A person taking any prescribed medicinal product or herbal medicine within 2 weeks of the first day of administration or taking or applying any OTC drug or vitamin preparation including artificial tears within 1 week (However, depending on the testee's judgment, other conditions may be appropriate to participate in the clinical trial)
- •Those who have received a whole blood donation within 2 months before the first administration of the drug for clinical trial, or have received a blood donation and blood transfusion within 1 month
- •Persons with hypersensitivity or clinically significant hypersensitivity reactions to medicinal products for use in clinical trials or drugs containing the same class of ingredients (eg. latanoprost, benzalkonium chloride)
- •Those who are not willing or able to comply with the lifestyle guidelines described in this Protocol,
- •An average of 10 smokers per day over the past three months or who can not quit smoking 48 hours before the first dose
- •Those who are planning to become pregnant during the trial period or who are not planning to use a reliable contraceptive method (Eg, use of contraceptives and transplants or intrauterine devices, infertility procedures (vasectomy, tubal ligation, etc.), blockage (condoms and spermicide), vaginal septa, vaginal sponges,
- •A person who is found to be unsuitable for clinical trial participation due to other reasons including clinical laboratory test results
研究组 & 干预措施
A single sequence, 3-period
Experimental
干预措施: D930, D565 (Drug)
结局指标
主要结局
AUCtau,ss of D930
时间窗: predose (0 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 24 h
Cmax,ss of D930
时间窗: predose (0 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 24 h
次要结局
- AUCt of D565(predose (0 h), 1min, 3min, 5min, 10min, 15min, 20min, 40min, 1, 2, 4 h)
- Cmax of D565(predose (0 h), 1min, 3min, 5min, 10min, 15min, 20min, 40min, 1, 2, 4 h)
- Tmax of D565(predose (0 h), 1min, 3min, 5min, 10min, 15min, 20min, 40min, 1, 2, 4 h)
- t1/2 of D565(predose (0 h), 1min, 3min, 5min, 10min, 15min, 20min, 40min, 1, 2, 4 h)
- AUCinf of D565(predose (0 h), 1min, 3min, 5min, 10min, 15min, 20min, 40min, 1, 2, 4 h)
- Ctrough, ss of D930(predose (0 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 24 h)
- Tmax,ss of D930(predose (0 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 24 h)
- t1/2 of D930(predose (0 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 24 h)
- AUCinf of D930(predose (0 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 24 h)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pharmacokinetics, -Dynamics and Safety of Intravenous Paracetamol in NeonatesPainFeverNCT00969176Universitaire Ziekenhuizen KU Leuven60
已完成
1 期
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsPostbariatric HypoglycemiaNCT06036784MBX Biosciences69
已完成
1 期
A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.HealthyNCT04081844Hanmi Pharmaceutical Company Limited31
已完成
1 期
Single and Multiple Dose Asian Bridging StudyHealthy SubjectsNCT01251731Eisai Inc.36
已完成
3 期
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3HIV InfectionsNCT00002124Pharmacia and Upjohn1,250